All Stories

F-star charts new path, splitting from invoX after 2023’s $161M acquisition

After a drawn-out acquisition that closed in 2023, U.K. biotech F-star Therapeutics is charting its own path as a private, independent company.

Apr 4, 2025 - 15:33
 0
F-star charts new path, splitting from invoX after 2023’s $161M acquisition
After a drawn-out acquisition that closed in 2023, U.K. biotech F-star Therapeutics is charting its own path as a private, independent company.
Read More

Tags:

Previous Article

Incentive scheme aims to increase international trains on HS1

Next Article

Human medicines European public assessment report (EPAR): Roclanda, latanoprost ...

Related Posts

UPDATE: Director of National Human Genome Research Institute departs in another Trump admin shakeup

UPDATE: Director of National Human Genome Research Inst...

Mar 21, 2025  0

Flagship’s Empress lays off 53% of staffers in push to get science to clinic

Flagship’s Empress lays off 53% of staffers in push to ...

Mar 18, 2025  0

Regeneron gene therapy improves hearing in 10 children with rare form of hearing loss

Regeneron gene therapy improves hearing in 10 children ...

Feb 24, 2025  0